NUVB Nuvation Bio Inc - Ordinary Shares - Class A
848
$3.08
$0.20
(6.10%)
| Watchers | 848 |
| 52-Wk Low | $0.95 |
| 52-Wk High | $4.16 |
| Market Cap | $764.37M |
| Volume | 475.00 |
| 52-Wk High | $4.16 |
| 52-Wk Low | $0.95 |
Nuvation Bio Reports First Quarter 2024 Financial Results and Provides Business UpdateBusiness Wire • 10 days ago
Nuvation Bio Inc. (NYSE: NUVB), a late-stage, global biopharmaceutical company tackling some of the greatest unmet needs in oncology by developing differentiated and novel therapeutic candidates...
Share to Feed
Nuvation Bio Inc. (NYSE: NUVB), a late-stage, global biopharmaceutical company tackling some of the greatest unmet needs in oncology by developing differentiated and novel therapeutic candidates...
Investors eyeing a purchase of Nuvation Bio Inc (NUVB) shares, but tentative about paying the going market price of 3.50/share, might benefit from considering selling puts among the alternative...
Nuvation Bio: Strong Buy Off The Acquisition Of A Late-Stage Lung Cancer Candidate...
Nuvation Bio: Strong Buy Off The Acquisition Of A Late-Stage Lung Cancer Candidate...
Nuvation Bio: Strong Buy Off The Acquisition Of A Late-Stage Lung Cancer Candidate...
BTIG Research upgraded shares of Nuvation Bio (NYSE:NUVB - Free Report) from a neutral rating to a buy rating in a research note published on Tuesday, MarketBeat reports. The firm currently has $5.00...
Nuvation Bio (NYSE:NUVB Get Free Report) was upgraded by equities research analysts at Jefferies Financial Group from a hold rating to a buy rating in a research...
Nuvation Bio Inc. (NYSE:NUVB Free Report) Wedbush issued their Q1 2025 earnings per share estimates for Nuvation Bio in a research note issued on Monday, March 25th. Wedbush...
Nuvation Bio Inc. (NYSE:NUVB Get Free Report) reached a new 52-week high during trading on Tuesday . The stock traded as high as $2.65 and last traded at $2.63, with a volume of 656006 shares...